Drug behemoth Sun Pharma, in a recent BSE filing disclosed about the US launch of ophthalmic solution Cequa used for the treatment of dry eye disease.It was done by one of the company's wholly-owned subsidiaries and the product offers the highest concentration of cyclosporine for ophthalmic use, permitted by USFDA

Cequa is indicated to generate tear formation and reduces eye dryness and associated problems.Sun Pharma also to come up with Cequa Support Specialty Pharmacy,to enable  insured patients to obtain Cequa .

According to Sun Pharma North America CEO, Abhay Gandhi "The US launch of Cequa, the third product in our growing ophthalmic portfolio, marks the availability of a truly innovative treatment option for patients with dry eye disease – an area with a high unmet medical need."